Kandoth C, Schultz N, Cherniack AD et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73

Article  PubMed  Google Scholar 

Corr B, Cosgrove C, Spinosa D, Guntupalli S (2022) Endometrial cancer: molecular classification and future treatments. BMJ Med 1:e000152

Article  PubMed  PubMed Central  Google Scholar 

Vermij L, Smit V, Nout R, Bosse T (2020) Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76:52–63

Article  PubMed  Google Scholar 

Who classification of tumours editorial board female genital tumours [Internet] (2020) Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th edn. vol 4. Available from: https://tumourclassification.iarc.who.int/chapters/34

Concin N, Matias-Guiu X, Vergote I et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31:12–39

Article  PubMed  Google Scholar 

Oaknin A, Bosse TJ, Creutzberg CL et al (2022) Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:860–877

Article  CAS  PubMed  Google Scholar 

Berek JS, Matias-Guiu X, Creutzberg C et al (2023) FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 162:383–394

Article  PubMed  Google Scholar 

Momeni-Boroujeni A, Nguyen B, Vanderbilt CM et al (2022) Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol 35:1269–1278

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826

Article  CAS  PubMed  PubMed Central  Google Scholar 

Šteiner P, Andreasen S, Grossmann P et al (2018) Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch 473:471–480

Article  PubMed  Google Scholar 

Ooi A, Oyama T, Nakamura R et al (2015) Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Mod Pathol 28:861–871

Article  CAS  PubMed  Google Scholar 

Stelloo E, Bosse T, Nout RA et al (2015) Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 28:836–844

Article  CAS  PubMed  Google Scholar 

Talhouk A, McAlpine JN (2016) New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 3:14

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talhouk A, McConechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802–813

Article  CAS  PubMed  Google Scholar 

León-Castillo A, Gilvazquez E, Nout R et al (2020) Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 250:312–322

Article  PubMed  PubMed Central  Google Scholar 

Stelloo E, Nout RA, Osse EM et al (2016) Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 22:4215–4224

Article  CAS  PubMed  Google Scholar 

Talhouk A, McConechy MK, Leung S et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113:299–310

Article  CAS  PubMed  PubMed Central  Google Scholar 

León-Castillo A, Britton H, McConechy MK et al (2020) Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250:323–335

Article  PubMed  PubMed Central  Google Scholar 

Bosse T, Nout RA, McAlpine JN et al (2018) Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 42:561–568

Article  PubMed  PubMed Central  Google Scholar 

Brett MA, Atenafu EG, Singh N et al (2021) Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and mutated endometrial endometrioid carcinoma grade. Int J Gynecol Pathol 40:116–123

Article  CAS  PubMed  Google Scholar 

Cui J, Chen X, Zhai Q et al (2023) A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. Diagn Pathol 18:19

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.endometrium.cz/doc/trusight-oncology-500-and-ht-data-sheet-1170-2018-010%20003.pdf

McAlpine JN, Chiu DS, Nout RA et al (2021) Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer 127:2409–2422

Article  PubMed  Google Scholar 

Veneris JT, Lee EK, Goebel EA et al (2019) Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol 153:471–478

Article  CAS  PubMed  Google Scholar 

Dong D, Lei H, Liu D et al (2021) POLE and mismatch repair status, checkpoint proteins and tumor-infiltrating lymphocytes in combination, and tumor differentiation: identify endometrial cancers for immunotherapy. Front Oncol 11:640018

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehnert JM, Panda A, Zhong H et al (2016) Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126:2334–2340

Article  PubMed  PubMed Central  Google Scholar 

Wang F, Zhao Q, Wang YN et al (2019) Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 5:1504–1506

Article  PubMed  PubMed Central  Google Scholar 

Slomovitz BM, Jiang Y, Yates MS et al (2015) Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33:930–936

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barra F, Evangelisti G, Ferro Desideri L et al (2019) Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs 28:131–142

Article  CAS  PubMed  Google Scholar 

Konstantinopoulos PA, Lee EK, Xiong N et al (2023) A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor-positive recurrent endometrial cancer. J Clin Oncol 41:599–608

Article  CAS  PubMed  Google Scholar 

Mirza MR, Bjorge L, Marme F et al (2020) LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial. Ann Oncol 31:S1160

Article  Google Scholar 

Moroney MR, Woodruff E, Qamar L et al (2021) Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog 60:511–523

Article  CAS  PubMed  Google Scholar 

Aghajanian C, Filiaci V, Dizon DS et al (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274–281

Article